Blog Posts

Analysis Of The Trastuzumab Biosimilar Market As Herceptin Exclusivity Nears An End

Posted April 24, 2019| Robert Browne

To expand on the Fuld + Company, Pharma Companies to Watch Report, Analyst Robert Browne drilled in on the Biosimilar Marketplace in this contributed piece to Biosimilar Development.

Biosimilar Market Analysis

Genentech’s Herceptin (trastuzumab) is a monoclonal antibody for HER2/neu receptors for use in HER2-overexpressing adjuvant and metastatic breast cancer and metastatic gastric or gastroesophageal junction adenocarcinoma. Herceptin has successfully cemented itself as a standard of care therapy and represents a multibillion-dollar pillar that centrally supports Roche’s oncology juggernaut, but this is changing. Since its original approval in 1998, Herceptin has enjoyed an exclusivity that has a fast-approaching terminus, with key patent expirations expected before the end of 2019.

Biosimilar competition includes an effort to significantly reduce the financial burden of biologic treatments on the healthcare system. Without direct competition within their treatment spaces, the prices of biologics have aggressively risen to an extent that underscores the need for increased biosimilar competition.

Within the last few years, the FDA has taken steps to approve more biosimilar products and has committed to providing for a competitive landscape. The three latest biosimilars to be approved by the FDA have all been biosimilars to Herceptin. Further, Pfizer’s Trazimera, the most recently approved trastuzumab biosimilar, has sparked intrigue. As a result, Genentech is bracing for Herceptin biosimilar commercial launches in 2019.

To learn more about the the Trastuzumab biosimilar competitive landscape, read the full article at Biolsimilar Development

 

Tags: , , , ,

Related Resources

Read More

Faces of Fuld: Q&A with Kimberlee Luce, Senior Director, Consumer Products + Retail

Kimberlee Luce has more than 20 years of experience in business research and consulting and has a unique blend of […]

Read More

How Cognitive Bias Can be a Bigger Threat than the Competition

Jennifer Swain, Senior Director at Fuld + Company, recently traveled to Atlanta to speak to an audience comprised of pricing […]

Read More

The Truth About Disruptive Innovation— Seeing Beyond the Buzzwords

Earlier this year, CEO Diane Borska, was asked to speak to business leaders from organizations of all dispositions. Below is […]

Subscribe to our mailing list for our latest updates: